There are over 100 known cannabinoids in cannabis, but many are only familiar with the well-known cannabinoids like cannabidiol or tetrahydrocannabinol. One lesser known cannabinoid is cannabidivarin (CBDV), a non-psychoactive cannabinoid that acts as an antiemetic and anticonvulsant. The cannabinoid is similar structurally to CBD, and like CBD, it may be able to help treat those who suffer from epilepsy and nausea. One study from 2013 found CBDV significantly reduced chemically-induced seizures. Another study from 2014 found the cannabinoid interactive with receptors responsible for detecting and regulating body temperatures and producing pain sensations. The Italian research team also noted CBDV reduced the duration and strength of simulated epileptic seizures in the brains of rats. Lastly, a study from 2013 published in the British Journal of Pharmacology found CBDV may have interacted with CCB1 receptors to reduce nausea in rats. The pharmaceutical company GW Pharmaceuticals is currently conducting clinical trials researching the use of CBDV.
This information has been provided by High Times and approved by our Chief Medical Officer.